Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy

Sjouke, 2015, Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome, Eur Heart J, 36, 560, 10.1093/eurheartj/ehu058 Slack, 1969, Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states, Lancet, 2, 1380, 10.1016/S0140-6736(69)90930-1 Austin, 2004, Familial hypercholesterolemia and coronary heart disease: a HuGE association review, Am J Epidemiol, 160, 421, 10.1093/aje/kwh237 Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 Versmissen, 2008, Efficacy of statins in familial hypercholesterolaemia: a long term cohort study, BMJ, 337, a2423, 10.1136/bmj.a2423 1991, Risk of fatal coronary heart disease in familial hypercholesterolaemia, BMJ, 303, 893, 10.1136/bmj.303.6807.893 Catapano, 2016, Atherosclerosis, 253, 281, 10.1016/j.atherosclerosis.2016.08.018 Landmesser, 2017, European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk, Eur Heart J, 38, 2245 NICE NIfHaCE, 2016, 1 Hovingh, 2013, Diagnosis and treatment of familial hypercholesterolaemia, Eur Heart J, 34, 962, 10.1093/eurheartj/eht015 Piepoli, 2016, Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106 Graham, 2007, Eur J Cardiovasc Prev Rehabil, 14, E1, 10.1097/01.hjr.0000277984.31558.c4 Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management, Eur Heart J, 36, 1012, 10.1093/eurheartj/ehv043 Mancia, 2014, 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension, Blood Press, 23, 3, 10.3109/08037051.2014.868629 American Diabetes Association, 2012, Diagnosis and classification of diabetes mellitus, Diabetes Care, 35, S64, 10.2337/dc12-s064 Goodyear, 2007, The declaration of Helsinki, BMJ, 335, 624, 10.1136/bmj.39339.610000.BE Pijlman, 2010, Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands, Atherosclerosis, 209, 189, 10.1016/j.atherosclerosis.2009.09.014 Besseling, 2014, Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers, Atherosclerosis, 233, 219, 10.1016/j.atherosclerosis.2013.12.020 Alonso, 2008, Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors, Atherosclerosis, 200, 315, 10.1016/j.atherosclerosis.2007.12.024 Besseling, 2016, Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality, J Am Coll Cardiol, 68, 252, 10.1016/j.jacc.2016.04.054 Khera, 2016, Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease, N Engl J Med, 375, 2349, 10.1056/NEJMoa1605086 Sijbrands, 2001, Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study, BMJ, 322, 1019, 10.1136/bmj.322.7293.1019 Jansen, 2004, The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients, J Intern Med, 256, 482, 10.1111/j.1365-2796.2004.01405.x Kotseva, 2016, EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries, Eur J Prev Cardiol, 23, 636, 10.1177/2047487315569401 Jorstad, 2013, Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial, Heart, 99, 1421, 10.1136/heartjnl-2013-303989 Watts, 2014, Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation, Int J Cardiol, 171, 309, 10.1016/j.ijcard.2013.11.025 Minneboo, 2017, Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease: The RESPONSE-2 Trial, J Am Coll Cardiol, 70, 318, 10.1016/j.jacc.2017.05.041 Galema-Boers, 2014, Predicting non-adherence in patients with familial hypercholesterolemia, Eur J Clin Pharmacol, 70, 391, 10.1007/s00228-013-1640-3 Katsiki, 2017, Lipoprotein (a) and Cardiovascular Risk: The Show Must go on, Curr Med Chem, 24, 989, 10.2174/0929867324666170112111948 Vuorio, 2017, Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a), Eur Heart J, 38, 3555, 10.1093/eurheartj/ehx546 Schmidt, 2017, PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease, Cochrane Database Syst Rev, CD011748 Sabatine, 2017, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664 Ginsberg, 2016, Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher, Cardiovasc Drugs Ther, 30, 473, 10.1007/s10557-016-6685-y Raal, 2015, PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, Lancet, 385, 331, 10.1016/S0140-6736(14)61399-4 Kazi, 2016, Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease, JAMA, 316, 743, 10.1001/jama.2016.11004